title: [Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
abstract: The surgical treatment of liver metastasis due to colorectal cancer can substantially modify the natural history of the disease, mainly when it is associated with effective medical treatment. Chemotherapy, via systemic or locoregional (intrahepatic) administration, has 2 possible objectives: as adjuvant treatment, to prevent or delay disease recurrence; as neo-adjuvant treatment, mainly interesting for the surgeon, to allow resective surgery in responding patients previously considered not-operable. Unfortunately, the severe immune deficiency associated with the advanced cancer negative impact on long-term outcome after any treatment (surgery, chemotherapy) is a limit for the clinical application of multidisciplinary treatments. Aim of this study is to review the possible different approaches to improve the clinical results, either as tumour response or overall survival, using an association of IL-2 with different chemotherapy procedures, in order to recover the locoregional and/or systemic immunodeficency. Several literature studies are worth of consideration not only for the biological activity reported, but also for the preliminary clinical results. At our Department, we have started a clinical experience in order to verify and confirm the results reported in these studies. The preliminary results seem to confirm an increase of chemotherapy activity obtained with an association of IL-2 immunotherapy with systemic therapy procedures and mainly with locoregional therapeutic programs.
authors.affiliation: Divisione di Chirurgia Generale II, Dipartimento di Scienze Chirurgiche e Terapia Intensiva, Clinica Chirurgica, Ospedale S. Gerardo Università degli Studi di Milano Bicocca, Monza (MI), Italy.
authors.forename: F
authors.initials: F
authors.lastname: Brivio
authors.forename: L
authors.initials: L
authors.lastname: Fumagalli
authors.forename: L
authors.initials: L
authors.lastname: Fattori
authors.forename: L
authors.initials: L
authors.lastname: Nespoli
authors.forename: M
authors.initials: M
authors.lastname: Denova
authors.forename: E
authors.initials: E
authors.lastname: Sargenti
authors.forename: A
authors.initials: A
authors.lastname: Nespoli
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003110:Colonic Neoplasms; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006499:Hepatic Artery; D006801:Humans; D007167:Immunotherapy; D007261:Infusions, Intra-Arterial; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D011182:Postoperative Care; D011300:Preoperative Care; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007376:Interleukin-2; D005472:Fluorouracil